Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)

NCT05127954 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05127954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05127954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
January 14, 2022
Completion date
January 31, 2028
Enrollment
1,200 (estimated)
Sites
113

Conditions

As the registry lists them; a condition with its own page is linked.

migraine